Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
Vivos Therapeutics (NASDAQ: VVOS) has announced that the American Medical Association (AMA) has issued new CPT® medical codes for all Vivos CARE oral medical devices, effective January 1, 2025. This development is expected to facilitate coverage and reimbursement by commercial medical insurance payers for the treatment of obstructive sleep apnea (OSA) in adults and children.
Vivos Chairman and CEO, Kirk Huntsman, stated that this approval will enable a larger number of patients to access their proprietary airway remodeling technology. The company believes this, along with recent regulatory approvals and their new alliance-based marketing and distribution model, will improve their position to drive revenue growth.
The AMA's CPT® 2025 code set includes 420 overall updates, with 270 new codes, 112 deletions, and 38 revisions. This approval follows Vivos' recent Medicare coverage approval and is seen as a major step towards making OSA treatment more accessible and affordable for patients nationwide, including children ages 6 to 17.
Vivos Therapeutics (NASDAQ: VVOS) ha annunciato che l'American Medical Association (AMA) ha emesso nuovi codici medici CPT® per tutti i dispositivi medici orali Vivos CARE, a partire dal 1° gennaio 2025. Questo sviluppo dovrebbe facilitare la copertura e il rimborso da parte dei pagatori di assicurazione sanitaria commerciali per il trattamento dell'apnea ostruttiva del sonno (OSA) negli adulti e nei bambini.
Il Presidente e CEO di Vivos, Kirk Huntsman, ha dichiarato che questa approvazione permetterà a un numero maggiore di pazienti di accedere alla loro tecnologia proprietaria di rimodellamento delle vie aeree. L'azienda è convinta che questo, insieme alle recenti approvazioni normative e al loro nuovo modello di marketing e distribuzione basato su alleanze, migliorerà la loro posizione per stimolare la crescita dei ricavi.
Il set di codici CPT® 2025 dell'AMA include 420 aggiornamenti complessivi, di cui 270 nuovi codici, 112 cancellazioni e 38 revisioni. Questa approvazione segue l'approvazione recente della copertura Medicare di Vivos ed è vista come un passo importante verso la resa del trattamento dell'OSA più accessibile e conveniente per i pazienti in tutto il paese, inclusi i bambini di età compresa tra 6 e 17 anni.
Vivos Therapeutics (NASDAQ: VVOS) ha anunciado que la Asociación Médica Americana (AMA) ha emitido nuevos códigos médicos CPT® para todos los dispositivos médicos orales Vivos CARE, con vigencia a partir del 1 de enero de 2025. Este desarrollo se espera que facilite la cobertura y reembolso por parte de los pagadores de seguros médicos comerciales para el tratamiento de la apnea obstructiva del sueño (OSA) en adultos y niños.
El presidente y CEO de Vivos, Kirk Huntsman, declaró que esta aprobación permitirá a un mayor número de pacientes acceder a su tecnología propietaria de remodelación de vías respiratorias. La compañía cree que esto, junto con las recientes aprobaciones regulatorias y su nuevo modelo de marketing y distribución basado en alianzas, mejorará su posición para impulsar el crecimiento de ingresos.
El conjunto de códigos CPT® 2025 de la AMA incluye un total de 420 actualizaciones, con 270 nuevos códigos, 112 eliminaciones y 38 revisiones. Esta aprobación sigue a la reciente aprobación de cobertura Medicare de Vivos y se considera un gran paso para hacer que el tratamiento de la OSA sea más accesible y asequible para los pacientes en todo el país, incluidos los niños de 6 a 17 años.
비보스 테라퓨틱스(VIVOS Therapeutics)(NASDAQ: VVOS)는 미국 의학 협회(AMA)가 모든 비보스 CARE 구강 의료 장치에 대한 새로운 CPT® 의료 코드를 2025년 1월 1일부터 시행한다고 발표했습니다. 이 개발은 상업 의료 보험 지불자에 의한 보장 및 환급을 용이하게 할 것으로 예상됩니다 성인 및 아동의 폐쇄성 수면 무호흡증(OSA) 치료를 위해.
비보스의 회장 겸 CEO인 커크 헌츠맨(Kirk Huntsman)은 이 승인이 더 많은 환자들이 자사의 독점적인 기도 리모델링 기술에 접근할 수 있도록 할 것이라고 밝혔습니다. 회사는 이것이 최근의 규제 승인 및 새로운 동맹 기반 마케팅 및 유통 모델과 함께 수익 성장 촉진을 위한 입지를 개선할 것이라고 믿고 있습니다.
AMA의 CPT® 2025 코드 세트에는 총 420개의 업데이트가 포함되어 있으며, 270개의 새로운 코드, 112개의 삭제 및 38개의 수정이 포함되어 있습니다. 이 승인은 비보스의 최근 메디케어 커버리지 승인을 따르며 OSA 치료를 아동을 포함한 전국의 환자들에게 더 접근 가능하고 저렴하게 만드는 중요한 단계로 여겨지고 있습니다.
Vivos Therapeutics (NASDAQ: VVOS) a annoncé que l'American Medical Association (AMA) a publié de nouveaux codes médicaux CPT® pour tous les dispositifs médicaux oraux Vivos CARE, à compter du 1er janvier 2025. Ce développement devrait faciliter la couverture et le remboursement par les assureurs de santé commerciaux pour le traitement de l'apnée obstructive du sommeil (OSA) chez les adultes et les enfants.
Le président et CEO de Vivos, Kirk Huntsman, a déclaré que cette approbation permettra à un plus grand nombre de patients d'accéder à leur technologie propriétaire de remodelage des voies respiratoires. L'entreprise estime que cela, ainsi que les récentes approbations réglementaires et son nouveau modèle de marketing et de distribution basé sur les alliances, améliorera sa position pour stimuler la croissance des revenus.
Le jeu de codes CPT® 2025 de l'AMA comprend un total de 420 mises à jour, avec 270 nouveaux codes, 112 suppressions et 38 révisions. Cette approbation fait suite à l'approbation récente de la couverture Medicare de Vivos et est considérée comme une étape majeure pour rendre le traitement de l'OSA plus accessible et abordable pour les patients à travers le pays, y compris les enfants de 6 à 17 ans.
Vivos Therapeutics (NASDAQ: VVOS) hat bekannt gegeben, dass die American Medical Association (AMA) neue CPT®-medizinische Codes für alle Vivos CARE-Oralmedizinprodukte zum 1. Januar 2025 herausgegeben hat. Diese Entwicklung wird voraussichtlich die Deckung und Rückerstattung durch gewerbliche Krankenversicherer erleichtern für die Behandlung von obstruktiver Schlafapnoe (OSA) bei Erwachsenen und Kindern.
Der Vorsitzende und CEO von Vivos, Kirk Huntsman, erklärte, dass diese Genehmigung es einer größeren Anzahl von Patienten ermöglichen wird, auf ihre proprietäre Technologie zur Umgestaltung der Atemwege zuzugreifen. Das Unternehmen glaubt, dass dies zusammen mit den jüngsten regulatorischen Genehmigungen und ihrem neuen Allianzen-basierten Marketing- und Vertriebsmodell die Position verbessern wird, um das Umsatzwachstum voranzutreiben.
Das CPT® 2025-Codeset der AMA umfasst insgesamt 420 Aktualisierungen, darunter 270 neue Codes, 112 Streichungen und 38 Überarbeitungen. Diese Genehmigung folgt auf die jüngste Genehmigung der Medicare-Abdeckung von Vivos und wird als wichtiger Schritt angesehen, um die Behandlung von OSA für Patienten im ganzen Land, einschließlich Kindern im Alter von 6 bis 17 Jahren, zugänglicher und erschwinglicher zu machen.
- New CPT® medical codes issued for all Vivos CARE oral medical devices
- Potential for increased insurance coverage and reimbursement
- Expanded access to Vivos' OSA treatment for a larger patient base
- Recent regulatory approvals and new marketing model position company for revenue growth
- Medicare coverage approval received a few months prior
- None.
Insights
The American Medical Association's (AMA) issuance of new CPT® medical codes for Vivos CARE oral medical devices is a significant development for Vivos Therapeutics. This decision will likely have substantial positive implications for the company's market penetration and revenue growth potential:
- The codes, effective from January 1, 2025, will facilitate billing and reimbursement by commercial medical insurance payers.
- Vivos' devices are uniquely FDA-cleared for treating moderate to severe obstructive sleep apnea (OSA).
- The codes apply to both adult and pediatric (ages 6-17) treatments, expanding the addressable market.
- This development complements recent Medicare coverage approval, further broadening accessibility.
The timing aligns well with Vivos' new alliance-based marketing and distribution model, potentially creating a synergistic effect on growth. However, investors should note that the impact on revenue may not be immediate, as the codes become effective in 2025 and adoption by insurers and healthcare providers may take time.
This regulatory development represents a potential inflection point for Vivos Therapeutics' financial outlook. Key financial implications include:
- Expanded market access: The new CPT® codes could significantly increase the pool of potential patients who can afford Vivos' treatments, potentially driving revenue growth.
- Improved reimbursement landscape: Easier billing processes may lead to faster payments and potentially higher reimbursement rates, positively impacting cash flow and profit margins.
- Competitive advantage: As the only FDA-cleared devices for moderate to severe OSA with these codes, Vivos may gain market share from competitors.
However, investors should consider that with a current market cap of only
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children
LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including obstructive sleep apnea (OSA) in adults and children, today announced the American Medical Association (AMA) has issued new CPT® medical codes applicable to all Vivos CARE oral medical devices, which will become effective January 1, 2025.
Vivos Chairman and CEO, Kirk Huntsman, stated, “This is exciting news for OSA patients and medical providers who treat sleep breathing disorders. Our CARE oral medical devices are the only ones cleared by the U.S. Food and Drug Administration for the treatment of moderate to severe OSA, and these new medical codes will now facilitate coverage and reimbursement by commercial medical insurance payers. From Vivos’ perspective, we believe this will enable a larger number of patients from most demographics to access our breakthrough, proprietary airway remodeling technology and more effectively treat their OSA. This development comes at an opportune moment for Vivos as our recent regulatory approvals, coupled with our new alliance-based marketing and distribution model and now these new codes put Vivos in an improved position to drive revenue growth.”
AMA Introduces 420 Updates in CPT® 2025, Including New Codes for Vivos
In a recent press release, the AMA explained, “The emergence of medical innovations, new technologies and cutting-edge procedures spurred most of the annual changes presented in the release of the Current Procedural Terminology (CPT®) 2025, the nation’s uniform data-sharing code set for medical procedures and services. There are 420 overall updates in the CPT® 2025 code set, including 270 new codes, 112 deletions, and 38 revisions.”
“The CPT® code set is the foundation for the efficient and effective exchange of standardized information in a data-driven health system…with the goal of delivering better patient care, improved outcomes and lower costs,” said AMA President Bruce A, Scott, M.D. “The latest updates to the CPT® code set reflect advancements in contemporary clinical practice.”
Mr. Huntsman concluded, “This AMA approval represents our latest regulatory and reimbursement milestone, following another important approval Vivos received for Medicare coverage just a few months ago. As part of our mission, Vivos has worked to make its innovative OSA treatment protocols available to more people so they can improve their lives. With these new CPT® codes, we are taking a major step towards making OSA treatment more accessible and affordable for patients nationwide, including children ages 6 to 17. This approval highlights our commitment to ensuring more people can receive the care they need while receiving greater support from their healthcare insurance plans.”
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults and children. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical, and cost-effective solution for treating mild to severe OSA in adults and moderate to severe OSA in children. It has proven effective in over 45,000 patients treated worldwide by more than 2,000 trained dentists.
The Vivos Method includes treatment regimens that employ proprietary CARE appliance therapy and other modalities that alter the size, shape, and position of the jaw and soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA in adults and moderate-to-severe OSA in children ages 6 to 17, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method. Vivos also employs a marketing and distribution model where it collaborates with sleep-treatment providers to offer patients OSA treatment options and help promote sales of its appliances. For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, including statements related to the acceptance and reimbursement rates of the new CPT codes. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the results of the CPT Code designations described herein on Vivos’ future revenues and results of operations or the anticipated benefits of the Company’s new marketing and distribution model) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all or maintain its Nasdaq listing and (v) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Vivos Investor Relations Contact:
Bradford Amman, CFO
investors@vivoslife.com
FAQ
When will the new CPT® codes for Vivos CARE oral medical devices become effective?
What age groups can benefit from Vivos' OSA treatment with the new CPT® codes?
How many updates are included in the AMA's CPT® 2025 code set?
What recent approval did Vivos (VVOS) receive prior to the CPT® code announcement?
